Elbert E. Heng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elbert E. Heng has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- John Ward MacArthur&ast
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA
4 shared publications Aravind Krishnan
Stanford University School of Medicine
3 shared publications- Daniel I. Alnasir
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA
3 shared publications - Alexander R. Berg
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA
2 shared publications - Alyssa C. Garrison
Stanford University School of Medicine
2 shared publications - Danielle M. Mullis
Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in American Journal of Transplantation
Nanomedicine in lung transplantation: Emerging solutions for clinical challenges
- 15 September 2026
- Published by Elsevier in American Journal of Transplantation
Open AccessNanomedicine in lung transplantation: Emerging solutions for clinical challenges
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045279
A New Era of Cardiothoracic Transplantation in Adults With Congenital Heart Disease
Background: A growing number of children with congenital heart disease survive to adulthood and require heart transplantation. This study evaluates the trends and outcomes of cardiothoracic transplantation for patients with adult congenital heart disease (ACHD) and describes our institution's 3 decades of experience. Methods: We identified all patients with ACHD who underwent first‐time cardiothoracic transplantation at our institution between December 1987 and December 2024. We compared characteristics and outcomes between a historical and contemporary cohort of transplant recipients. Results: In total, 196 patients with ACHD underwent cardiothoracic transplantation. The annual rate of cardiothoracic transplantation in patients with ACHD doubled after 2018. The first era of heart transplantation in patients with ACHD from 1987 to 2018 is defined predominantly by heart–lung transplantation, most commonly for isolated septal defect. The second era since 2018 is defined by sicker, more complex patients. Following the United Network for Organ Sharing heart allocation policy change, recipients were older, underwent more prior cardiac surgeries, were more likely to be hospitalized, and were more likely to have single‐ventricle anatomy with Glenn/Fontan palliation. Comparing the 2 eras, 1‐year survival rates for all patients with ACHD were comparable (81% versus 81%, P =0.939) and improved for heart‐only transplant recipients (72.5% versus 90.7%, P =0.066). Conclusions: The number and complexity of patients with ACHD undergoing cardiothoracic transplantation has grown, with a significant increase in patients who previously underwent palliative surgeries. With increased use of medical and surgical adjuncts, excellent long‐term survival for transplant recipients is achievable.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045279
Open AccessA New Era of Cardiothoracic Transplantation in Adults With Congenital Heart Disease
Background: A growing number of children with congenital heart disease survive to adulthood and require heart transplantation. This study evaluates the trends and outcomes of cardiothoracic transplantation for patients with adult congenital heart disease (ACHD) and describes our institution's 3 decades of experience. Methods: We identified all patients with ACHD who underwent first‐time cardiothoracic transplantation at our institution between December 1987 and December 2024. We compared characteristics and outcomes between a historical and contemporary cohort of transplant recipients. Results: In total, 196 patients with ACHD underwent cardiothoracic transplantation. The annual rate of cardiothoracic transplantation in patients with ACHD doubled after 2018. The first era of heart transplantation in patients with ACHD from 1987 to 2018 is defined predominantly by heart–lung transplantation, most commonly for isolated septal defect. The second era since 2018 is defined by sicker, more complex patients. Following the United Network for Organ Sharing heart allocation policy change, recipients were older, underwent more prior cardiac surgeries, were more likely to be hospitalized, and were more likely to have single‐ventricle anatomy with Glenn/Fontan palliation. Comparing the 2 eras, 1‐year survival rates for all patients with ACHD were comparable (81% versus 81%, P =0.939) and improved for heart‐only transplant recipients (72.5% versus 90.7%, P =0.066). Conclusions: The number and complexity of patients with ACHD undergoing cardiothoracic transplantation has grown, with a significant increase in patients who previously underwent palliative surgeries. With increased use of medical and surgical adjuncts, excellent long‐term survival for transplant recipients is achievable.
- 17 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 337-346
Ex-vivo heart perfusion attenuates early post-transplant risk after prolonged agonal period in DCD heart transplantation
- 17 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 337-346
Ex-vivo heart perfusion attenuates early post-transplant risk after prolonged agonal period in DCD heart transplantation
- Top Cited Papers
- 1 May 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (5) , 1065-1085
Hemodynamics and Wall Mechanics of Vascular Graft Failure
Blood vessels are subjected to complex biomechanical loads, primarily from pressure-driven blood flow. Abnormal loading associated with vascular grafts, arising from altered hemodynamics or wall mechanics, can cause acute and progressive vascular failure and end-organ dysfunction. Perturbations to mechanobiological stimuli experienced by vascular cells contribute to remodeling of the vascular wall via activation of mechanosensitive signaling pathways and subsequent changes in gene expression and associated turnover of cells and extracellular matrix. In this review, we outline experimental and computational tools used to quantify metrics of biomechanical loading in vascular grafts and highlight those that show potential in predicting graft failure for diverse disease contexts. We include metrics derived from both fluid and solid mechanics that drive feedback loops between mechanobiological processes and changes in the biomechanical state that govern the natural history of vascular grafts. As illustrative examples, we consider application-specific coronary artery bypass grafts, peripheral vascular grafts, and tissue-engineered vascular grafts for congenital heart surgery as each of these involves unique circulatory environments, loading magnitudes, and graft materials.
- 1 May 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (5) , 1065-1085
Top Cited PapersHemodynamics and Wall Mechanics of Vascular Graft Failure
Blood vessels are subjected to complex biomechanical loads, primarily from pressure-driven blood flow. Abnormal loading associated with vascular grafts, arising from altered hemodynamics or wall mechanics, can cause acute and progressive vascular failure and end-organ dysfunction. Perturbations to mechanobiological stimuli experienced by vascular cells contribute to remodeling of the vascular wall via activation of mechanosensitive signaling pathways and subsequent changes in gene expression and associated turnover of cells and extracellular matrix. In this review, we outline experimental and computational tools used to quantify metrics of biomechanical loading in vascular grafts and highlight those that show potential in predicting graft failure for diverse disease contexts. We include metrics derived from both fluid and solid mechanics that drive feedback loops between mechanobiological processes and changes in the biomechanical state that govern the natural history of vascular grafts. As illustrative examples, we consider application-specific coronary artery bypass grafts, peripheral vascular grafts, and tissue-engineered vascular grafts for congenital heart surgery as each of these involves unique circulatory environments, loading magnitudes, and graft materials.